search
Back to results

ABO-GLYC in Type 2 Diabetes

Primary Purpose

Type2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
ABO-GLYC
ABO-GLYC Placebo
Sponsored by
Aboca Spa Societa' Agricola
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type2 Diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female patients with diagnosis of type 2 diabetes, aged 18-75
  2. HbA1c at screening between 6.5% and 7.5%
  3. Last 2 HbA1c values in the last 12 months between 6.5% and 7.5%
  4. Intolerance to metformin without unquestionable indication to other oral hypoglycemic agents
  5. BMI 25-38 kg/m2
  6. Willing and able to understand and sign the informed consent and complete the patient diary provided
  7. Women participant of childbearing age should be negative to pregnancy test (performed on blood), and will have to use an appropriate contraceptive method throughout the study.

Exclusion Criteria:

  1. Micro and macrovascular complication of diabetes in advanced stage (i.e., proliferative diabetic retinopathy; chronic renal failure III-IV stage KDOQI)
  2. Chronic gastro-intestinal disease
  3. Heavy smoker subjects
  4. Alcohol abuse
  5. Chronic liver and kidney disease (AST or ALT values > 2.5 UNL or plasma creatinine > 1.5 mg/dl)
  6. Previous major gastrointestinal surgery
  7. History of eating disorders
  8. Pregnancy or lactation
  9. Use of food supplements containing in particular but not limited to fibers and polysaccharides, in the last six months with frequency and dosage such as to interfere with the study.
  10. Autoimmune diseases
  11. Known hypersensitivity to any of the components of the product.
  12. Any condition which prevent subject participation in the opinion of the principal investigator.

Sites / Locations

  • Azienda Ospedaliera Padova

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Group A: ABO-GLYC

Group B: Placebo

Arm Description

Libramed

Outcomes

Primary Outcome Measures

Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
HbA1c measure
Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
Tmax
Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
Cmax

Secondary Outcome Measures

Improvement of markers of glycemic variability (plasma glucose level)
Composite measurement of standard deviation and coefficient of variation of the plasma glucose level
Improvement of markers of glycemic variability (MAGE)
mean amplitude of glucose excursion (MAGE)
Improvement of markers of glycemic variability (HBGl)
high blood glycemic index (HBGI)
Improvement of markers of glycemic variability (LBGI)
, low blood glycemic index (LBGI)
Improvement of markers of glycemic variability (hypo/hyper glycemia)
percentage of time spent in hypoglycemia or hyperglycemia
Improvement of markers of metabolic status (BMI)
Weight and height will be combined to report BMI in kg/m^2,total cholesterol, LDL triglycerides or NEFA, HDL and in the percentage of body fat determined by bioimpedentiometry
Improvement of markers of glyco-oxidative stress
Measurement of receptor for advanced glycation endproducts (RAGE), Malondialdehyde (MDA) and/or oxidized LDL
Improvement of markers of inflammation
Measurement of TNF-alpha, IL-1, IL-6
Improvement of markers of metabolic status (lipid profile)
Measurement of total cholesterol, HDL cholesterol and Tryglycerides
Improvement of markers of metabolic status (body composition)
percentage of body fat determined by bioimpedentiometry
Evaluation of gut microbiome changes (bacteria population)
Evaluation of bacteria population
Evaluation of gut microbiome changes (SCFA)
Evaluation of short change fatty acids measurements (SCFA)
Improvement in markers of insulin resistance
Measurement of HOMA-IR and QUICKI
Improvement in markers of insulin secretion after standardized meal.
Measurement of insulin and c-peptide secretion measured during the glycemic curve after a standardized meal
Evaluation of the dietary adherence
Perceived Dietary Adherence Questionnaire (PDAQ). The PDAQ uses a 5-point Likert scale to assess perceived difficulty.
Adverse events (AEs) evaluation and product tolerability.
Adverse event will be recorded during the course of the study, after the signature of the informed consent
Control of the glycemia.
The data from the glycemic diary will be monitored to assess the good control of the glycemia as measured by Self Monitoring of Blood Glucose (SMBG).

Full Information

First Posted
May 15, 2018
Last Updated
June 28, 2022
Sponsor
Aboca Spa Societa' Agricola
Collaborators
Latis S.r.l., Fondazione Edmund Mach
search

1. Study Identification

Unique Protocol Identification Number
NCT03568409
Brief Title
ABO-GLYC in Type 2 Diabetes
Official Title
Efficacy of ABO-GLYC on Glycemic and Metabolic Status of Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
June 1, 2017 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aboca Spa Societa' Agricola
Collaborators
Latis S.r.l., Fondazione Edmund Mach

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluation of the improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
86 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A: ABO-GLYC
Arm Type
Experimental
Arm Description
Libramed
Arm Title
Group B: Placebo
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
ABO-GLYC
Other Intervention Name(s)
Libramed
Intervention Description
3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
Intervention Type
Other
Intervention Name(s)
ABO-GLYC Placebo
Intervention Description
3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
Primary Outcome Measure Information:
Title
Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
Description
HbA1c measure
Time Frame
Week0 and Week24
Title
Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
Description
Tmax
Time Frame
Week0 and Week24
Title
Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
Description
Cmax
Time Frame
Week0 and Week24
Secondary Outcome Measure Information:
Title
Improvement of markers of glycemic variability (plasma glucose level)
Description
Composite measurement of standard deviation and coefficient of variation of the plasma glucose level
Time Frame
Week0 to Week24
Title
Improvement of markers of glycemic variability (MAGE)
Description
mean amplitude of glucose excursion (MAGE)
Time Frame
Week0 to Week24
Title
Improvement of markers of glycemic variability (HBGl)
Description
high blood glycemic index (HBGI)
Time Frame
Week0 to Week24
Title
Improvement of markers of glycemic variability (LBGI)
Description
, low blood glycemic index (LBGI)
Time Frame
Week0 to Week24
Title
Improvement of markers of glycemic variability (hypo/hyper glycemia)
Description
percentage of time spent in hypoglycemia or hyperglycemia
Time Frame
Week0 to Week24
Title
Improvement of markers of metabolic status (BMI)
Description
Weight and height will be combined to report BMI in kg/m^2,total cholesterol, LDL triglycerides or NEFA, HDL and in the percentage of body fat determined by bioimpedentiometry
Time Frame
Week0 to Week24
Title
Improvement of markers of glyco-oxidative stress
Description
Measurement of receptor for advanced glycation endproducts (RAGE), Malondialdehyde (MDA) and/or oxidized LDL
Time Frame
Week0 to Week24
Title
Improvement of markers of inflammation
Description
Measurement of TNF-alpha, IL-1, IL-6
Time Frame
Week0 to Week24
Title
Improvement of markers of metabolic status (lipid profile)
Description
Measurement of total cholesterol, HDL cholesterol and Tryglycerides
Time Frame
Week0 to Week24
Title
Improvement of markers of metabolic status (body composition)
Description
percentage of body fat determined by bioimpedentiometry
Time Frame
Week0 to Week24
Title
Evaluation of gut microbiome changes (bacteria population)
Description
Evaluation of bacteria population
Time Frame
Week 0, Week 1, Week 12, Week 24
Title
Evaluation of gut microbiome changes (SCFA)
Description
Evaluation of short change fatty acids measurements (SCFA)
Time Frame
Week 0, Week 1, Week 12, Week 24
Title
Improvement in markers of insulin resistance
Description
Measurement of HOMA-IR and QUICKI
Time Frame
Week 0 and Week 24
Title
Improvement in markers of insulin secretion after standardized meal.
Description
Measurement of insulin and c-peptide secretion measured during the glycemic curve after a standardized meal
Time Frame
Week 0 and Week 24
Title
Evaluation of the dietary adherence
Description
Perceived Dietary Adherence Questionnaire (PDAQ). The PDAQ uses a 5-point Likert scale to assess perceived difficulty.
Time Frame
Week0 to Week24
Title
Adverse events (AEs) evaluation and product tolerability.
Description
Adverse event will be recorded during the course of the study, after the signature of the informed consent
Time Frame
Week0 to Week24
Title
Control of the glycemia.
Description
The data from the glycemic diary will be monitored to assess the good control of the glycemia as measured by Self Monitoring of Blood Glucose (SMBG).
Time Frame
Week0 to Week24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients with diagnosis of type 2 diabetes, aged 18-75 HbA1c at screening between 6.5% and 7.5% Last 2 HbA1c values in the last 12 months between 6.5% and 7.5% Intolerance to metformin without unquestionable indication to other oral hypoglycemic agents BMI 25-38 kg/m2 Willing and able to understand and sign the informed consent and complete the patient diary provided Women participant of childbearing age should be negative to pregnancy test (performed on blood), and will have to use an appropriate contraceptive method throughout the study. Exclusion Criteria: Micro and macrovascular complication of diabetes in advanced stage (i.e., proliferative diabetic retinopathy; chronic renal failure III-IV stage KDOQI) Chronic gastro-intestinal disease Heavy smoker subjects Alcohol abuse Chronic liver and kidney disease (AST or ALT values > 2.5 UNL or plasma creatinine > 1.5 mg/dl) Previous major gastrointestinal surgery History of eating disorders Pregnancy or lactation Use of food supplements containing in particular but not limited to fibers and polysaccharides, in the last six months with frequency and dosage such as to interfere with the study. Autoimmune diseases Known hypersensitivity to any of the components of the product. Any condition which prevent subject participation in the opinion of the principal investigator.
Facility Information:
Facility Name
Azienda Ospedaliera Padova
City
Padova
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ABO-GLYC in Type 2 Diabetes

We'll reach out to this number within 24 hrs